<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3283">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528329</url>
  </required_header>
  <id_info>
    <org_study_id>PR0013</org_study_id>
    <nct_id>NCT04528329</nct_id>
  </id_info>
  <brief_title>Anosmia and / or Ageusia and Early Corticosteroid Use</brief_title>
  <official_title>Time to Recover of Anosmia and / or Ageusia and Early Corticosteroid Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ClinAmygate</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ClinAmygate</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Time to recover of Anosmia and / or ageusia and early corticosteroid use
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a study of dexamethasone kinetics in two groups of 15 patients with community-acquired
      pneumonia, one group was treated with dexamethasone 6 mg/day by mouth and the other with 4
      mg/day intravenously. The apparent volume of distribution was 1 L/kg in both groups, but the
      half-life after oral administration was approximately 7 hours, and after intravenous
      administration 9 hours. The bioavailability of oral dexamethasone was 81% (95% CI = 54-121%).
      However, the biological half-life of dexamethasone is much longer, of the order of 36-54 h
      compared with 18-36 h for prednisolone.

      Time to recover of Anosmia and / or ageusia and early corticosteroid use
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>one to 6 weeks</time_frame>
    <description>Time to recovery from anosmia and / or agusia</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Covid19</condition>
  <condition>Anosmia</condition>
  <arm_group>
    <arm_group_label>Early CS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>early use of dexamethasone as early as the laboratory confirmation of inflammation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late CS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone is to be used lately upon the deterioration of cases</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Early-Dexamethasone</intervention_name>
    <description>early use of dexamethasone as early as laboratory evidence of high inflammatory markers</description>
    <arm_group_label>Early CS</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Late dexamethazone</intervention_name>
    <description>Use of dexamethasone on deterioration of the cases with increased severity</description>
    <arm_group_label>Late CS</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any case with COVID-19

          -  Age more than or equal to 18 years

          -  Mild to moderate severity

        Exclusion Criteria:

          -  Diabetes

          -  Any contra-indication for the interventional drug

          -  Mentally disabled cases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emad R Issak, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assalam Clinics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emad R Issak, MD</last_name>
    <phone>01272228989</phone>
    <email>dr.emad.r.h.issak@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asalam</name>
      <address>
        <city>Maadi</city>
        <state>Cairo</state>
        <zip>11433</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emad R Issak, MD</last_name>
      <phone>01272228989</phone>
      <email>dr.emad.r.h.issak@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Spoorenberg SM, Deneer VH, Grutters JC, Pulles AE, Voorn GP, Rijkers GT, Bos WJ, van de Garde EM. Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia. Br J Clin Pharmacol. 2014 Jul;78(1):78-83. doi: 10.1111/bcp.12295.</citation>
    <PMID>24400953</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olfaction Disorders</mesh_term>
    <mesh_term>Ageusia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

